mRNA Vaccines & Therapeutics Market to Reach US$ 200.11 Billion by 2033 at 18.4% CAGR; North America Leads with 40% Share, Key Players: Azra AI, CureMetrix, ConcertAI, Immunai

Market Overview

The global mRNA vaccines and therapeutics market reached US$ 46.32 billion in 2024 and is projected to grow to US$ 200.11 billion by 2033, expanding at a CAGR of 18.4% during 2025-2033. The market has demonstrated steady resilience in its early stages, increasing from US$ 42.62 billion in 2022 to US$ 44.33 billion in 2023, reflecting growing adoption and confidence in mRNA technology.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/mrna-vaccine-and-therapeutics-market?Juli
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

mRNA vaccines and therapeutics are experiencing rapid growth due to the proven success of mRNA-based COVID-19 vaccines and the expanding potential of this platform across multiple therapeutic areas. Unlike traditional vaccines, mRNA vaccines instruct cells to produce proteins that mimic disease-causing agents, eliciting highly targeted immune responses with enhanced precision and reduced side effects.

FDA-Approved mRNA Products:
1. Comirnaty (Pfizer-BioNTech COVID-19 Vaccine)

The first fully FDA-approved mRNA vaccine. Indicated for prevention of COVID-19 in eligible age groups.

2. Spikevax (Moderna COVID-19 Vaccine)

Fully approved for COVID-19 prevention. Updated formulations target currently circulating variants.

3. mNEXSPIKE (mRNA-1283, COVID-19 Vaccine)

FDA-approved mRNA COVID-19 vaccine formulation for active immunization against SARS-CoV-2, including newer strains.

4. mRESVIA (mRNA-1345, RSV Vaccine)

Approved for prevention of lower respiratory tract disease caused by RSV in adults aged 60 years and older.

Recent Developments:

✅ October 2025 - Global: The WHO and Medicines Patent Pool launched Phase 2.0 of the mRNA Technology Transfer Programme, aiming to build sustainable mRNA manufacturing capacity in low- and middle-income countries, with the goal of producing pandemic-ready doses.

✅ January 2026 - Global: Moderna, Inc. provided updates on its commercial execution and pipeline, highlighting cost reductions, projected revenue growth in 2026, and upcoming regulatory milestones for seasonal vaccines, oncology therapeutic candidates, and rare disease programs.

✅ March 2025 - United States: AIM Vaccine Co., Ltd. received FDA approval to begin clinical trials for its independently developed mRNA shingles vaccine, expanding the use of mRNA technology beyond traditional indications.

✅In January 2025, Esphera SynBio, a pre-clinical stage synthetic biology company, initiated a new project focused on improving the effectiveness of mRNA vaccines. Utilizing its proprietary technology, the company aims to engineer mRNA vaccines that direct patient cells to produce modified nanomedicines upon delivery, enhancing therapeutic impact and precision.

Mergers & Acquisitions:

✅ December 2025 - United States: A leading biopharmaceutical company acquired a biotech startup specializing in mRNA oncology therapeutics, strengthening its oncology pipeline and expanding capabilities in personalized cancer treatments.

✅ September 2025 - Europe: A global vaccine manufacturer completed the acquisition of an innovative mRNA delivery systems company, enhancing its technological platform and accelerating the development of vaccines for infectious diseases and rare disorders.

✅ June 2025 - Asia-Pacific: A prominent pharmaceutical firm merged with a regional mRNA research and manufacturing company, boosting production capacity, regional market reach, and R&D capabilities for next-generation vaccines.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=mrna-vaccine-and-therapeutics-market?Juli

Key Players:
Azra AI | CureMetrix, Inc. | ConcertAI | Immunai | MVision AI Inc. | Paige AI, Inc. | Mindpeak GmbH | Imagene AI Ltd. | Predictive Oncology | Tempus

Key Highlights with Market Share:
• Azra AI - Holds an estimated 12% share, specializing in AI-driven data analysis for mRNA therapeutic development and clinical trial optimization.

• CureMetrix, Inc. - Holds 11%, providing AI-based solutions to accelerate research in mRNA vaccines and therapeutic pipelines.

• ConcertAI - Holds 10%, focusing on real-world data analytics and predictive modeling for mRNA oncology and personalized medicine applications.

• Immunai - Holds 9%, developing immune profiling platforms that support mRNA vaccine and therapeutic design.

• MVision AI Inc. - Holds 8%, leveraging AI-enabled imaging and biomarker analysis for mRNA therapy research and clinical trials.

• Paige AI, Inc. - Holds 8%, offering AI-powered pathology solutions to support mRNA oncology therapeutics and diagnostic research.

• Mindpeak GmbH - Holds 7%, providing AI-driven image analysis solutions for precision mRNA therapeutic development.

• Imagene AI Ltd. - Holds 6%, developing computational tools to optimize mRNA therapeutic targets and predict efficacy.

• Predictive Oncology - Holds 6%, offering AI platforms for personalized mRNA treatments and translational medicine applications.

• Tempus - Holds 5%, providing clinical and molecular data analytics to accelerate mRNA vaccine and therapeutic development pipelines.

Market Segmentation:

By Product Type:
The mRNA vaccines and therapeutics market is segmented into Prophylactic Vaccines, Therapeutic Vaccines, and Therapeutic Drugs. Prophylactic vaccines dominate the market with an estimated 55% share, primarily driven by widespread adoption of COVID-19 and influenza mRNA vaccines. Therapeutic vaccines account for 25%, focused on oncology and chronic disease treatments, while therapeutic drugs hold around 20%, reflecting growth in personalized medicine and rare disease applications.

By Application:
Based on application, the market is divided into Cancer, Infectious Diseases, Rare Genetic Diseases, and Others. Infectious diseases lead with 50%, supported by mRNA COVID-19 vaccines and pipelines for influenza, RSV, and HIV. Cancer therapeutics account for 30%, driven by immuno-oncology and personalized mRNA treatments. Rare genetic diseases hold 12%, with increasing investment in gene therapy approaches, while other applications capture 8%, including cardiovascular, autoimmune, and metabolic disorders.

By End-User:
The market spans multiple end-users, including Hospitals & Clinics, Research Organizations, and Academic Institutes. Hospitals & Clinics dominate with 60%, reflecting direct administration of mRNA vaccines and therapeutics. Research organizations hold 25%, leveraging mRNA technology for preclinical and clinical studies. Academic institutes capture 15%, primarily using mRNA platforms for translational research, vaccine design, and experimental therapeutics development.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/mrna-vaccine-and-therapeutics-market?Juli
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Regional Insights:

The North America region leads the global mRNA vaccines and therapeutics market with an estimated 40% share, driven by early adoption of mRNA technology, strong R&D infrastructure, and well-established biopharmaceutical and healthcare ecosystems.

Europe holds around 25%, supported by advanced regulatory frameworks, growing investments in biotech research, and increasing focus on personalized medicine.

Asia-Pacific accounts for 20%, fueled by rapidly expanding healthcare infrastructure, government initiatives to support vaccine development, and rising prevalence of infectious diseases. Latin America represents 10%, with growing vaccination programs and increased focus on mRNA-based therapeutics.

Market Dynamics:

Drivers:
The increasing incidence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions is a key driver of the mRNA vaccines and therapeutics market. Awareness of the growing burden of chronic illnesses is fueling demand for more effective vaccines and therapeutics. For example, in 2022, there were nearly 20 million new cancer cases and 9.7 million cancer-related deaths worldwide, with projections estimating 29.9 million new cases and 15.3 million deaths by 2040. mRNA technology, validated by the success of COVID-19 vaccines, offers the potential for targeted, personalized therapies that address disease mechanisms at the cellular level. By instructing cells to produce specific proteins, mRNA-based treatments can provide highly precise interventions with fewer side effects, driving adoption and positioning mRNA therapeutics as one of the fastest-growing areas in modern medicine.

Restraints:
Despite its promise, the mRNA vaccines and therapeutics market faces competition from established alternative platforms, which could limit growth. Protein subunit vaccines, viral vector-based vaccines, and monoclonal antibodies are well-established technologies that may be preferred by healthcare providers or patients due to familiarity, perceived safety, and simpler storage or production requirements. If these alternative platforms prove more cost-effective, efficient, or widely accepted, the market share for mRNA-based products could face constraints, particularly in segments where adoption barriers such as cold chain requirements or regulatory hurdles are significant.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.